Although previous studies described correlations between serum ApoC-II expression and the risk of occurrence or progression in cancer, including pancreatic cancer [8], colorectal cancer [32], and breast cancer [33], to the best of our knowledge, this is the first report to provide the prognostic value of the serum ApoC-II level in CC treated with RT. This evidence concerns the gene APOC2 and breast carcinoma.